<DOC>
	<DOCNO>NCT00002493</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know treatment regimen effective endometrial cancer . PURPOSE : Randomized phase III trial compare radiation therapy chemotherapy treat patient advanced endometrial cancer .</brief_summary>
	<brief_title>Radiation Therapy Compared With Combination Chemotherapy Treating Patients With Advanced Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall survival , progression-free interval , pattern failure maximally debulked patient stage III/IV endometrial carcinoma treat whole-abdominal irradiation vs. doxorubicin/cisplatin . II . Compare incidence type acute late adverse event observe two treatment regimen . III . Compare change fatigue , elimination , neurologic impairment impact quality life patient treat two regimen . IV . Assess difference short-term versus long-term impact quality life two treatment group . V. Compare quality-of-life outcome time two treatment group . OUTLINE : Randomized study . Arm I : Radiotherapy . Whole-abdominal irradiation use equipment photon energies range 6 25 MV . Arm II : 2-Drug Combination Chemotherapy . Doxorubicin , DOX , NSC-123127 ; Cisplatin , CDDP , NSC-119875 . PROJECTED ACCRUAL : It anticipate 355 patient enter 7.4 year .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathological stage III/IV endometrial carcinoma histology ( include clear cell serous papillary carcinoma ) The following extent disease eligible : Positive adnexa Tumor invade serosa Positive pelvic node Positive paraaortic node Involvement bowel mucosa Intraabdominal metastasis Positive pelvic washing Vaginal involvement within radiotherapy field Hysterectomy bilateral salpingooophorectomy ( BSO ) require residual tumor great 2 cm site Selective pelvic paraaortic lymph node sample optional patient stage III/IV disease criterion If paraaortic node positive , scalene node must negative biopsy chest CT must negative intrathoracic disease The following disease condition exclude : Parenchymal liver metastasis Lung metastasis Positive inguinal node Positive scalene node Recurrent disease Protocol therapy must begin within 8 week surgery PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 03 Hematopoietic : WBC least 3,000/mm3 Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal AST great 3 time normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : Left ventricular ejection fraction normal Other : No past concomitant malignancy nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : Prior progestational agent allow No prior endocrine therapy Radiotherapy : No prior pelvic abdominal radiotherapy Surgery : Hysterectomy BSO require Pelvic paraaortic lymph node sample optional ( see Disease Characteristics )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>endometrial adenocarcinoma</keyword>
	<keyword>endometrial adenosquamous cell carcinoma</keyword>
	<keyword>endometrial adenoacanthoma</keyword>
	<keyword>endometrial papillary serous carcinoma</keyword>
	<keyword>endometrial clear cell carcinoma</keyword>
	<keyword>psychosocial effect cancer treatment</keyword>
</DOC>